Literature DB >> 1489138

Bronchoalveolar lavage cellularity. The distribution in normal volunteers.

R K Merchant1, D A Schwartz, R A Helmers, C S Dayton, G W Hunninghake.   

Abstract

Bronchoalveolar lavage (BAL) is used to obtain inflammatory cells from the lung. For clinical research, parametric statistics are frequently used to compare cells present in BAL of patients with lung disease with cells present in BAL of normal subjects. To determine if these populations can be compared in this manner we performed BAL on 111 never-smoking, normal volunteers and determined: (1) the mean, median, standard deviation, and range of the cells in BAL; (2) whether the data are normally distributed and satisfy the criteria for use of parametric statistical analysis. The BAL cellularity was expressed as a percentage of total cells, cells per milliliter return, and total cells per lavage. Regardless of the means of expression, no measure of BAL cellularity (total cells, macrophages, lymphocytes, neutrophils, or eosinophils) conformed to the normal (bell-shaped) distribution when tested for goodness of fit with the G statistic (all p < 0.001). The lack of fit to the normal distribution was not substantially altered by either the method of expressing the data (i.e., cells per milliliter, total cells, or percent of cells) or log transformation of the data. The poor fit in all cases resulted from clumping of the data about the mean and large tails. The percent of cells were, therefore, tested for goodness of fit to the Poisson distribution, a distribution of discrete variables. The neutrophil and eosinophil percentages resulted in an excellent fit to the Poisson distribution, but macrophage and lymphocyte percentages did not.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1489138     DOI: 10.1164/ajrccm/146.2.448

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  19 in total

1.  Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects.

Authors:  J E Conte; J A Golden; M McQuitty; J Kipps; E T Lin; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection.

Authors:  Stephan Schwander; Keertan Dheda
Journal:  Am J Respir Crit Care Med       Date:  2010-11-12       Impact factor: 21.405

3.  Bronchoalveolar lavage total cell count in interstitial lung diseases--does it matter?

Authors:  Joanna Domagała-Kulawik; Tomasz Skirecki; Marta Maskey-Warzechowska; Hanna Grubek-Jaworska; Ryszarda Chazan
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

4.  Analysis of bronchoalveolar lavage fluid in patients with chronic hepatitis C before and after treatment with interferon alpha.

Authors:  S Yamaguchi; K Kubo; K Fujimoto; T Honda; M Sekiguchi; T Sodeyama
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

5.  Electronic versus Combustible Cigarette Effects on Inflammasome Component Release into Human Lung.

Authors:  MuChun Tsai; Min-Ae Song; Christian McAndrew; Theodore M Brasky; Jo L Freudenheim; Ewy Mathé; Joseph McElroy; Sarah A Reisinger; Peter G Shields; Mark D Wewers
Journal:  Am J Respir Crit Care Med       Date:  2019-04-01       Impact factor: 21.405

6.  Effect of segmental bronchoalveolar lavage on quantitative computed tomography of the lung.

Authors:  Luke M Gabe; Kimberly M Baker; Edwin J R van Beek; Gary W Hunninghake; Joseph M Reinhardt; Eric A Hoffman
Journal:  Acad Radiol       Date:  2011-07       Impact factor: 3.173

7.  Elastinolytic activity of alveolar macrophages in smoking-associated pulmonary emphysema.

Authors:  T Muley; M Wiebel; V Schulz; W Ebert
Journal:  Clin Investig       Date:  1994-03

8.  Role of T-lymphocytes in the resolution of endotoxin-induced lung injury.

Authors:  P E Morris; J Glass; R Cross; D A Cohen
Journal:  Inflammation       Date:  1997-06       Impact factor: 4.092

9.  Characterization of bronchoalveolar lavage T cell subsets in sarcoidosis on the basis of CD57, CD4 and CD8.

Authors:  T Kurumagawa; S Seki; H Kobayashi; Y Koike; S Kanoh; H Hiraide; K Motoyoshi
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

10.  Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin.

Authors:  J E Conte; J A Golden; S Duncan; E McKenna; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.